Namenda Switching Lawsuit May Go Actavis’ Way On Appeal
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral arguments in Second Circuit attract overflow crowd in case that prompted amicus briefs from PhRMA, BIO and many others.
You may also be interested in...
Evergreening Gets Trimmed? Product Switching Suits On Namenda, Others Proceeding
New York judge blocks Actavis from halting sales of Namenda IR to force switch to extended release version; Pennsylvania judge lets product hopping claims proceed against Reckitt in Suboxone antitrust litigation.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.